Expression of chemerin correlates with a favorable prognosis in patients with non-small cell lung cancer

Laboratory Medicine

Volumn 42, Issue 9, 2011, Pages 553-557

  Zhao, Shen ^a,b   Li, Chao ^b   Ye, Yun Bin ^b   Peng, Feng ^b   Chen, Qiang ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b FUJIAN PROVINCIAL TUMOR HOSPITAL   (China)

Author keywords

Chemerin; Natural killer cells; Non small cell lung cancer; Prognosis

Indexed keywords

CHEMERIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CELL INFILTRATION; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE;

EID: 80052619795     PISSN: 00075027     EISSN: 19437730     Source Type: Journal    
DOI: 10.1309/LMWW79NITS6ZADPT     Document Type: Article

References (21)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med. 2006;355:570-580.
3. Singletary SE, Allred C, Ashley P, et al. Staging system for breast cancer: Revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am. 2003;83:803-819.
4. Kaminski N, Krupsky M. Gene expression patterns, prognostic and diagnostic markers, and lung cancer biology. Chest. 2004;125:111S-115S.
5. Amerio P, Frezzolini A, Feliciani C, et al. Eotaxins and CCR3 receptor in inflammatory and allergic skin diseases: Therapeutical implications. Curr Drug Targets Inflamm Allergy. 2003;2:81-94.
6. Zernecke A, Weber C. Chemokines in the vascular inflammatory response of atherosclerosis. Cardiovasc Res. 2010;86:192-201.
7. Zucchetto A, Tripodo C, Benedetti D, et al. Monocytes/macrophages but not T lymphocytes are the major targets of the CCL3/CCL4 chemokines produced by CD38(+)CD49d(+) chronic lymphocytic leukaemia cells. Br J Haematol. 2010;150:111-113.
8. Maghazachi AA. Role of chemokines in the biology of natural killer cells. Curr Top Microbiol Immunol. 2010;341:37-58.
9. He S, Wang L, Wu Y, et al. CCL3 and CCL20-recruited dendritic cells modified by melanoma antigen gene-1 induce anti-tumor immunity against gastric cancer ex vivo and in vivo. J Exp Clin Cancer Res. 2010;29:37.
10. Parolini S, Santoro A, Marcenaro E, et al. The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. Blood. 2007;109:3625-3632.
11. Skrzeczyńska-Moncznik J, Stefańska A, Zabel BA, et al. Chemerin and the recruitment of NK cells to diseased skin. Acta Biochim Pol. 2009;56:355-360.
12. Schneider BJ. Non-small cell lung cancer staging: Proposed revisions to the TNM system. Cancer Imaging. 2008;8:181-185.
13. Bozaoglu K, Bolton K, McMillan J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology. 2007;148:4687-4694.
14. Pfau D, Stepan H, Kratzsch J, et al. Circulating levels of the adipokine chemerin in gestational diabetes mellitus. Horm Res Paediatr. 2010;74:56-61.
15. Lehrke M, Becker A, Greif M, et al. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol. 2009;161:339-344.
16. Iwakiri S, Mino N, Takahashi T, et al. Higher expression of chemokine receptor CXCR7 is linked to early and metastatic recurrence in pathological stage I nonsmall cell lung cancer. Cancer. 2009;115:2580-2593.
17. Coscia M, Biragyn A. Cancer immunotherapy with chemoattractant peptides. Semin Cancer Biol. 2004;14:209-218.
18. Moser B, Wolf M, Walz A, et al. Chemokines: Multiple levels of leukocyte migration control. Trends Immunol. 2004;25:75-84.
19. Shurin GV, Ferris RL, Tourkova IL, et al. Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. J Immunol. 2005;174:5490-5498.
20. Ando S, Kimura H, Iwai N, et al. The significance of tumour markers as an indication for mediastinoscopy in non-small cell lung cancer. Respirology. 2003;8:163-167.
21. Daigo Y, Nakamura Y. From cancer genomics to thoracic oncology: Discovery of new biomarkers and therapeutic targets for lung and esophageal carcinoma. Gen Thorac Cardiovasc Surg. 2008;56:43-53.